A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
暂无分享,去创建一个
Ravi Salgia | Andrey Khramtsov | R. Salgia | G. Karczmar | A. Khramtsov | Salman Ahmed | J. Hetzel | R. Jagadeeswaran | Greg Karczmar | V. Nallasura | Jeremy T Hetzel | Neelu Puri | Ramasamy Jagadeeswaran | Vidya Nallasura | N. Puri | Salman Ahmed
[1] T. Pawson,et al. Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.
[2] David I. Smith,et al. A role for common fragile site induction in amplification of human oncogenes. , 2002, Cancer cell.
[3] G. V. Vande Woude,et al. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. , 1996, Oncogene.
[4] Gayatry Mohapatra,et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Baselga,et al. Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.
[6] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[7] R. Salgia,et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.
[8] J. Christensen,et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.
[9] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[10] T. Nakamura,et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. , 1994, Oncogene.
[11] Lothar Hennighausen,et al. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways , 2003, Oncogene.
[12] J. Christensen,et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.
[13] J. Christensen,et al. A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.
[14] W. Hung,et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. , 2003, Cancer research.
[15] R. Salgia,et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.
[16] T. Pawson,et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Stamos,et al. The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.
[18] R. Sharp,et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Schemper,et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. , 1990, Cancer research.
[20] Ravi Salgia,et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.